OR WAIT null SECS
February 12, 2024
The agency’s safety committee stressed the risk of potential adverse reactions involved with taking Paxlovid (nirmatrelvir, ritonavir) in combination with certain immunosuppressants.
February 09, 2024
The three non-commercial developers of ATMPs will benefit from enhanced support from the agency.
February 08, 2024
Through a €2.7 billion (US$2.9 billion) acquisition of MorphoSys, Novartis will get pelabresib, a late-stage drug candidate in development for cancer treatment.
February 05, 2024
The CDMOs are joining together to offer end-to-end development and manufacturing services for protein expression systems and viral vectors in Europe.
Novo Holdings has entered into a merger agreement with Catalent and will acquire Catalent in a deal valued at $16.5 billion.
February 04, 2024
NICE has recommended the use of AbbVie's Tepkinly as a treatment option for eligible adults with diffuse large B-cell lymphoma.
February 03, 2024
ProductLife Group has announced its acquisition of Australian company Commercial Eyes.
February 02, 2024
The agency will coordinate intra-regional medicines regulation to strengthen the African regulatory network.
Under a new collaboration, Lonza and Oxford Nanopore aim to commercialize a CGMP-validated test for advanced analysis of mRNA products.
The UK’s IRP increases flexibility and will help speed up product approvals and patient access to medicines.